Zobrazeno 1 - 10
of 280
pro vyhledávání: '"Edwin R, Parra"'
Autor:
Ignacio I Wistuba, Amelia Insa, Mariano Provencio, Bartomeu Massutí, Federico Garrido, Edwin R Parra, Delvys Rodriguez-Abreu, Manuel Cobo, Joaquín Casal-Rubio, Ernest Nadal, Javier Martín-López, Diego Megías, Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Alex Martinez-Marti, Isidoro Barneto Aranda, Santiago Viteri, Marta Casarrubios, Cristina Martinez-Toledo, Virginia Calvo, Marta Molina-Alejandre, Francisco Perea, Javier de Castro, Joaquín Mosquera Martínez, Rafael Muñoz-Viana, Natalia Aptsiauri, Francisco Ruiz-Cabello
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 10 (2024)
Background Loss of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH) are common events implicated in the primary resistance of non-small cell lung cancer (NSCLC) to immunotherapy. However, there is no data on periopera
Externí odkaz:
https://doaj.org/article/8c3f29b6cb394ac3ba9e2fc1ab852402
Autor:
Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We i
Externí odkaz:
https://doaj.org/article/6a562891133f4ee084b42c34b2d77b3e
Autor:
Jose A. Karam, Pavlos Msaouel, Cara L. Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita, Amishi Y. Shah, Ignacio I. Wistuba, Enrica Marmonti, Dzifa Y. Duose, Edwin R. Parra, Luisa Maren Solis Soto, Caddie Laberiano-Fernandez, Marisa Lozano, Alice Abraham, Max Hallin, Curtis D. Chin, Peter Olson, Hirak Der-Torossian, Xiaohong Yan, Nizar M. Tannir, Christopher G. Wood
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in
Externí odkaz:
https://doaj.org/article/8affada371c5430f97f977800c38a734
Autor:
Raphael E. Steiner, Edwin R. Parra, Francisco Vega, Lei Feng, Jason R. Westin, Sattva S. Neelapu, Paolo Strati, Michael R. Green, Christopher R. Flowers, Luisa M. Solis, Ignacio I. Wistuba, Sairah Ahmed, Ranjit Nair, Fredrick B. Hagemeister, Mansoor Noorani, Mario L. Marques-Piubelli
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-5 (2023)
Abstract Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, p
Externí odkaz:
https://doaj.org/article/e3114eba62f94495bc871889c61eb0f9
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundThe liver is the most typical site of metastatic disease for patients with colorectal cancer (CRC), and up to half the patients with CRC will develop colorectal liver metastasis (CLM). Studying the tumor microenvironment, particularly macro
Externí odkaz:
https://doaj.org/article/ab52bc79a30b41468b6c8bfee576424e
Autor:
Shailbala Singh, Leticia C. Clemente, Edwin R. Parra, Amanda Tchakarov, Chao Yang, Yisheng Li, James P. Long, Cassian Yee, Jamie S. Lin
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Acute kidney injury (AKI) occurs in ~20% of patients receiving immune checkpoint inhibitor (ICI) therapy; however, only 2–5% will develop ICI-mediated immune nephritis. Conventional tests are nonspecific in diagnosing disease pathology and invasive
Externí odkaz:
https://doaj.org/article/e3961439724d4a29a218e7146b8e9728
Autor:
Mario L. Marques-Piubelli, Luisa M. Solis, Edwin R. Parra, Luis Malpica Castillo, Sushanth Gouni, Ranjit Nair, Dai Chihara, Marina Konopleva, Ignacio I. Wistuba, Swaminathan P. Iyer, Francisco Vega, Paolo Strati
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/6130830d682f4eefbb3bb5566d89c087
Autor:
Rossana Lazcano, Carmelia M. Barreto, Ruth Salazar, Fernando Carapeto, Raymond S. Traweek, Cheuk H. Leung, Swati Gite, Jay Mehta, Davis R. Ingram, Khalida M. Wani, Kim-Anh T. Vu, Edwin R. Parra, Wei Lu, Jianling Zhou, Russell G. Witt, Brandon Cope, Prapassorn Thirasastr, Heather Y. Lin, Christopher P. Scally, Anthony P. Conley, Ravin Ratan, J. Andrew Livingston, Alexandra M. Zarzour, Joseph Ludwig, Dejka Araujo, Vinod Ravi, Shreyaskumar Patel, Robert Benjamin, Jennifer Wargo, Ignacio I. Wistuba, Neeta Somaiah, Christina L. Roland, Emily Z. Keung, Luisa Solis, Wei-Lien Wang, Alexander J. Lazar, Elise F. Nassif
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionUndifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) are effective in 20% of UPS patients. We characterize the immune
Externí odkaz:
https://doaj.org/article/0f3178fc4ae44b07859cc53a24e0f97e
Autor:
Tina Cascone, Annikka Weissferdt, Myrna C. B. Godoy, William N. William, Cheuk H. Leung, Heather Y. Lin, Sreyashi Basu, Shalini S. Yadav, Apar Pataer, Kyle G. Mitchell, Md Abdul Wadud Khan, Yushu Shi, Cara Haymaker, Luisa M. Solis, Edwin R. Parra, Humam Kadara, Ignacio I. Wistuba, Padmanee Sharma, James P. Allison, Nadim J. Ajami, Jennifer A. Wargo, Robert R. Jenq, Don L. Gibbons, J. Jack Lee, Stephen G. Swisher, Ara A. Vaporciyan, John V. Heymach, Boris Sepesi
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Granulomatous/sarcoid-like lesions have been reported in patients treated with immune checkpoint inhibitors (ICIs). Here the authors report the occurrence of “nodal immune flare”, an apparent radiological cancer progression in the nodes character
Externí odkaz:
https://doaj.org/article/02f55269e7f9462fb8c8389a4b130848
Autor:
Ignacio I Wistuba, Andrew Futreal, Xuemei Wang, Arvind Dasari, Cathy Eng, Scott Kopetz, Edwin R Parra, Cara L Haymaker, Eduardo Vilar, Robert A Wolff, Kanwal Raghav, Michael J Overman, Younghee Lee, Benny Johnson, Luisa Maren Solis Soto, Jane V Thomas, Van K Morris, Bryan K Kee, Christine M Parseghian, Daniele Lorenzini, Caddie Laberiano-Fernandez, Anuj Verma, Wenhua Lang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background Monotherapy with immune checkpoint blockade is ineffective for patients (pts) with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). This study investigates whether the combination of trametinib (T) with durvalumab (D) can a
Externí odkaz:
https://doaj.org/article/df046ec2d0ff48c99275fc303b6ac56b